-
Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi Syndrome
Read more: Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi SyndromePamplona, Navarra – 23 October 2026 – Palobiofarma announced results from its Phase 2 study of PBF-999, its investigational PDE10A inhibitor for the treatment of Prader-Willi syndrome (PWS), presented at…
